Adverse events of SARS-CoV-2 vaccination in patients with inflammatory rheumatic disease during repeated vaccination: An observational cohort study

To give further insights into the safety of SARS-CoV-2 vaccinations in patients with inflammatory rheumatic diseases (IRDs) compared to healthy individuals and to highlight changes over the course of repeated vaccinations. In this single-centre study, SARS-CoV-2 vaccinated IRD patients were recruited from the hospital of the University of Munich. Healthcare workers served as the control group. Adverse events following each vaccination were assessed using questionnaires. Descriptive statistics and non-parametric tests were used to illustrate the differences between IRD patients and the control group. Between January 1, 2021, and Septemper 30, 2022, 235 IRD patients (60.4% female) and 102 healthy individuals (66.7% female) were enrolled in this study. The frequency of patients who experienced adverse events after the first vaccination (140 [59.6%]) was significantly lower compared to the control group (86 [84.3%]) (OR = 0.274 [95% CI: 0.151-0.497]; P < 0.0001). The same was true after the second vaccination (patients: 138 [58.7%]; controls: 80 [78.4%]) (OR = 0.391 [0.228-0.670]; P < 0.001), and after the third vaccination (123 [56.4%]; 70 [69.3%]) (OR = 0.573 [0.348-0.946]; P = 0.029). Local side effects occurred with similar frequency in both groups. However, systemic effects occurred significantly less frequently in patients after all vaccinations than in controls (1. vaccination 97 [41.3%] to 61 [59.8%]: OR = 0.472 [0.294-0.759], P = 0.002; 2. vaccination 91 [38.7%] to 60 [58.8%]: OR = 0.442 [0.275-0.710], P < 0.001; 3. vaccination: 85 [39.0%] to 52 [51.5%]: OR = 0.602 [0.374-0.969], P = 0.036). SARS-CoV-2 vaccines were well tolerated by patients with IRDs. They experienced systemic side effects less frequently in patients than in healthy controls, suggesting a possible association between IRDs/immunosuppressive therapies and attenuation of vaccination reactions. Further research is needed to determine the cause of these differences.

Authors

Institutions

Publication Details

Journal
Rheumatology International
Published
2025-10-23
DOI
https://doi.org/10.1007/s00296-025-06013-z
Citations
1
Primary Topic
SARS-CoV-2 and COVID-19 Research
Type
article
Field-Weighted Citation Impact
1.40
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Adverse events of SARS-CoV-2 vaccination in patients with inflammatory rheumatic disease during repeated vaccination: An observational cohort study

Lea Grümme, F. Ullrich, Alla Skapenko, Christina Gebhardt et al.
1 citations
Rheumatology International
SARS-CoV-2 and COVID-19 Research
1.40
article

Adverse events of SARS-CoV-2 vaccination in patients with inflammatory rheumatic disease during repeated vaccination: An observational cohort study

Lea Grümme, F. Ullrich, Alla Skapenko, Christina Gebhardt, Julia Lichtnekert, Hendrik Schulze‐Koops, Stefan Wolfrum, Delila Singh, Liam Huppke
article en
1 citations

Abstract

To give further insights into the safety of SARS-CoV-2 vaccinations in patients with inflammatory rheumatic diseases (IRDs) compared to healthy individuals and to highlight changes over the course of repeated vaccinations. In this single-centre study, SARS-CoV-2 vaccinated IRD patients were recruited from the hospital of the University of Munich. Healthcare workers served as the control group. Adverse events following each vaccination were assessed using questionnaires. Descriptive statistics and non-parametric tests were used to illustrate the differences between IRD patients and the control group. Between January 1, 2021, and Septemper 30, 2022, 235 IRD patients (60.4% female) and 102 healthy individuals (66.7% female) were enrolled in this study. The frequency of patients who experienced adverse events after the first vaccination (140 [59.6%]) was significantly lower compared to the control group (86 [84.3%]) (OR = 0.274 [95% CI: 0.151-0.497]; P < 0.0001). The same was true after the second vaccination (patients: 138 [58.7%]; controls: 80 [78.4%]) (OR = 0.391 [0.228-0.670]; P < 0.001), and after the third vaccination (123 [56.4%]; 70 [69.3%]) (OR = 0.573 [0.348-0.946]; P = 0.029). Local side effects occurred with similar frequency in both groups. However, systemic effects occurred significantly less frequently in patients after all vaccinations than in controls (1. vaccination 97 [41.3%] to 61 [59.8%]: OR = 0.472 [0.294-0.759], P = 0.002; 2. vaccination 91 [38.7%] to 60 [58.8%]: OR = 0.442 [0.275-0.710], P < 0.001; 3. vaccination: 85 [39.0%] to 52 [51.5%]: OR = 0.602 [0.374-0.969], P = 0.036). SARS-CoV-2 vaccines were well tolerated by patients with IRDs. They experienced systemic side effects less frequently in patients than in healthy controls, suggesting a possible association between IRDs/immunosuppressive therapies and attenuation of vaccination reactions. Further research is needed to determine the cause of these differences.

Rheumatology InternationalVol. 45(11)
LMU Klinikum (DE), Ludwig-Maximilians-Universität München (DE)
Openalex Percentile: Top 15%
SARS-CoV-2 and COVID-19 Research
1.40
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.